Oculis (NASDAQ:OCS) Stock Price Expected to Rise, Stifel Nicolaus Analyst Says

Oculis (NASDAQ:OCS) had its price objective increased by investment analysts at Stifel Nicolaus from $35.00 to $40.00 in a report released on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Stifel Nicolaus’ price objective would indicate a potential upside of 92.35% from the company’s current price.

A number of other analysts also recently issued reports on the stock. Lifesci Capital began coverage on shares of Oculis in a report on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 price target for the company. JPMorgan Chase & Co. assumed coverage on Oculis in a research report on Friday. They issued an “overweight” rating and a $38.00 price objective for the company. Needham & Company LLC reissued a “buy” rating and set a $36.00 target price on shares of Oculis in a research note on Tuesday, November 11th. Wall Street Zen raised Oculis from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research report on Wednesday, October 8th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $41.50.

Oculis Price Performance

OCS stock traded up $1.32 during mid-day trading on Friday, reaching $20.80. The company’s stock had a trading volume of 47,737 shares, compared to its average volume of 56,035. The company has a current ratio of 4.47, a quick ratio of 4.47 and a debt-to-equity ratio of 0.02. The company’s 50 day moving average is $20.10 and its two-hundred day moving average is $18.85. Oculis has a fifty-two week low of $14.00 and a fifty-two week high of $23.08. The stock has a market cap of $1.09 billion, a PE ratio of -8.25 and a beta of 0.32.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.10. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%.The business had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.23 million. Equities research analysts expect that Oculis will post -2.09 EPS for the current year.

Institutional Investors Weigh In On Oculis

Large investors have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. purchased a new position in Oculis in the first quarter valued at $2,499,000. Compagnie Lombard Odier SCmA lifted its position in shares of Oculis by 11.5% during the 2nd quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company’s stock worth $1,883,000 after buying an additional 10,000 shares during the last quarter. Pivotal bioVenture Partners Investment Advisor LLC grew its holdings in shares of Oculis by 32.4% during the first quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 2,300,774 shares of the company’s stock worth $43,784,000 after purchasing an additional 563,078 shares during the last quarter. Woodline Partners LP grew its stake in Oculis by 65.8% during the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after buying an additional 33,265 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in shares of Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after acquiring an additional 878 shares during the period. 22.30% of the stock is owned by hedge funds and other institutional investors.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.